Pediatric lisinopril ingestions reported to Texas poison control centers.
Lisinopril is not recommended for use by young children. This study attempted to identify factors associated with serious outcomes in pediatric lisinopril ingestions. Cases for this study were lisinopril ingestions by children age < or =5 years reported to Texas poison control centers during 1998-2005. The percentage of cases involving serious medical outcomes was identified for selected variables and evaluated for statistical significance by calculating the rate ratio (RR) and 95% confidence interval (CI). Of 691 total cases, 26 (3.8%) involved a serious outcome. Higher serious outcome rates were found with a maximum dose of >4 mg/kg (RR: 2.54, CI: 0.05-25.62), or >80 mg (RR: 7.85; CI: 1.73-29.29), or five or more tablets (RR: 8.18; CI: 2.73-22.54), or the patient was already at or en route to a health care facility when the poison control center was contacted (RR: 13.93; CI: 3.68-77.78), or referred to a health care facility by the poison control center (RR: 33.49; CI: 9.04-194.94). The management of patients with severe outcomes was more likely to involve health care facilities. This information is useful for drafting triage guidelines for the management of pediatric lisinopril ingestions.
Forrester
M B
MB
Texas Department of State Health Services, 1100 W 49th Street, Austin, TX 78756, USA. mathias.forrester@dshs.state.tx.us
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000506:poisoning*; D000959:Antihypertensive Agents / Q000506:poisoning*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D017706:Lisinopril / Q000506:poisoning*; D008297:Male; D011039:Poison Control Centers / Q000706:statistics & numerical data*; D011041:Poisoning / Q000628:therapy; D013781:Texas
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D017706:Lisinopril